research First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.



Ahmedabad, Gujarat, India
Mumbai, Maharashtra, India
New York, NY, United States
Monterrey, Nuevo Leon, Mexico
São Paulo, SP, Brazil
Piracicaba, SP, Brazil